Skip to main content

45 Days Out, the Rules for Telehealth Prescriptions Are Still in a Document Nobody Can Read

The DEA's pandemic-era telemedicine flexibilities expire December 31. The permanent replacement has been under White House review since late summer. Buprenorphine patients have a floor. Many others don't.

ByThe Rize NewsroomNovember 16, 20262 min readOpioids

Somewhere tonight a person in rural Arizona will take a buprenorphine dose prescribed by a clinician they have only ever seen on a phone screen. So will someone across the country picking up an ADHD prescription from a telehealth practice, or a benzodiazepine for panic. Every one of those prescriptions rests on a temporary federal rule that runs out in 45 days.

Six weeks before the deadline, the people whose medicine depends on the rule still can’t read the rule.

The DEA and HHS extended the pandemic-era telemedicine flexibilities, which let clinicians prescribe controlled medications without ever seeing the patient in person, for a fourth time, through December 31, 2026. The permanent replacement, a “special registration” system first proposed in January 2025, went to the White House’s regulatory review office in late summer, and it has not been published. The federal regulatory agenda pointed to November. November is half over.

Buprenorphine patients have a floor, and it’s important to get it right. A separate final rule lets clinicians start buprenorphine by telehealth, including by phone alone, for an initial six-month supply after checking the state prescription monitoring database. After that, more prescriptions require “other forms of telemedicine as authorized under the Controlled Substances Act, or” an in-person evaluation. Without the flexibilities or a special registration, those other forms get much narrower. Your state’s own telehealth and prescribing laws apply on top of all of this. The patients most exposed are those who have been on telehealth-only buprenorphine past six months and never had an in-person visit, along with people getting stimulants and benzodiazepines entirely online.

This isn’t a fight over an unproven idea. In a study of 175,778 Medicare patients, people who got opioid use disorder care by telehealth during the pandemic had 33% lower odds of a medically treated overdose and 27% higher odds of staying on medication. That study is observational and can’t prove telehealth caused the difference, but it points the opposite way from the fear the 2008 law was written around. We made this argument when the last renewal came down to the wire. It’s the same argument now, with less time.

For providers, this week: pull a list of every patient on a controlled medication you’ve never seen in person, and count months since each buprenorphine patient’s telehealth start. Book the in-person or video visits now, while there’s room on the calendar. If you get your medicine this way, ask at your next appointment, “What happens to my prescription on January 1?” and don’t hang up without an answer.

We’ll track it in Technology & Innovation and our opioids coverage. But nobody should have to refresh the Federal Register to find out whether they can stay on the medicine that’s keeping them alive.

Filed Under

policytreatmentTelehealth RulesDEAMAT — BuprenorphinePrescription StimulantsFederalThe Treatment Gap

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section